C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication
Category: Publication
Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstractand the posterPoster Presentation
Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.AACR 2023Download the poster herePoster Presentation
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.AACR 2023Download the poster herePoster Presentation
Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.AACR 2023Download the poster herePoster Presentation
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.AACR 2023Download the poster herePoster Presentation
Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.AACR 2023Download the poster herePoster Presentation
TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
